Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Myovant Sciences's annualizedNet Income for the quarter that ended in Mar. 2022 was $-237.1 Mil. Myovant Sciences's average total tangible assets for the quarter that ended in Mar. 2022 was $562.2 Mil. Therefore, Myovant Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2022 was -42.18%.
The historical rank and industry rank for Myovant Sciences's Return-on-Tangible-Asset or its related term are showing as below:
MYOV'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -207.23 Med: -77.77 Max: -31.62
Current: -31.62
During the past 7 years, Myovant Sciences's highest Return-on-Tangible-Asset was -31.62%. The lowest was -207.23%. And the median was -77.77%.
MYOV's Return-on-Tangible-Asset is ranked better than 54.05% of 1556
companies
in the Biotechnology industry
Industry Median: -34.64
vs MYOV: -31.62
Myovant Sciences Return-on-Tangible-Asset Historical Data
The historical data trend for Myovant Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Return-on-Tangible-Asset
-94.13
-187.31
-207.23
-61.41
-33.09
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Return-on-Tangible-Asset
-43.42
-33.95
-12.27
-39.53
-42.18
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Return-on-Tangible-Asset Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2022) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Myovant Sciences Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.32(3.28%) Volume: 625,329 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
